6Pizcueta MP,Pique JM,Bosch J,et al. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circuation of rats with portsl hypertension[J].Br J pharmacology, 1992,105(1):184～190
7Lee Fy,Albillos A, Colombato LA, et al. The role of nitric oxide in the vascular Hyporesposiveness to methoxanine in portal hypertensive rats [J]. Hepatology, 1992,16(4): 1 043～ 1 048
5Bernardi M, Gulberg V, Colantoni A. et al. Plasma endothelin-1 and-3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J Hepatol, 1996,24:161-168.
6Marteau P, Bailer F, Chazouilleres O, et al. Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. Hepatology, 1989,9:820-823.
7Zhang JX, Bauer M, Clemens MG, Vessel and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am J Physiol,1995,269:269-277.
2Jin-Hua Zeng, Zhen Yang, Jun Xu, Ming-Lian Qiu and Ke-Can Lin Department of Surgery, First Affiliated Hospital of Fu-jian Medical University, Fuzhou 350004 , China Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.Down-regulation of the gax gene in smooth muscle cells of the splenic vein of portal hypertension patients[J].Hepatobiliary & Pancreatic Diseases International,2006,5(2):242-245. 被引量：4
3Hui Cao, Jia Xu, Rong Hua, Fang-Bin Meng, Jiang-Feng Qiu and Zhi-Yong Wu Department of Surgery, Renji Hospital, Shanghai Second Medical University, Shanghai 200127, China.Expression of cyclooxygenase in hyperdynamic portal hypertensive rats[J].Hepatobiliary & Pancreatic Diseases International,2006,5(2):252-256. 被引量：8
3Sorbi D,Gost out CJ,Peura D,et al.An assessment of the manage-ment of acute bleeding varices:a multicenter prospective memberbased study [J].Am J Gastroenterol,2003,98(11):2424-2434.
4Moren OA,Barcen AR,Blazquez J,et al.Partial splenic emboliza-tion for the treatment of hypersplenism in cirriiotic HIV/ HCV pa-tients prior to pegylated interferon and ribavirin [J].Antivir Ther,2004,9(6):1027-1030.
5Jung HS,Kalva SP,Greenfield AJ,et al.TIPS:Comparison ofshunt patency and clinical outcomes between bare stents and ex-panded polytetrafluoroethylene stent-grafts [J].Journal of Vascularand Interventional Radiology,2009,2(20):180-185.
6Bureau C,Pagan JC,Layrargues GP,et al.Patency of stents cov-ered with polytetrafuoroethylene in patients treated by transjugularintrahepatic portosystemic shunts:longterm results of a randomizedmulticentre study [J].Liver International,2007,27(6):742-747.
7Hausegger KA,Kamel F,Georgieva B,et al.Transjugular intrahe-patic portosystemic shunt creation with the viatorr expanded polytet-rafluoFoethylene covered stent-graft [J].JVIRj 2004,15:239-248.
8Saxon RR.A new era for transjugular intrahepatic portosystemicshunts [J].JVIR,2004,15(3):217-219.
9Cura M,Cura A,Suri R,et al.Causes of TIPS dysfunction [J].AmJ Roentgenol,2008,191(6):1751-1757.
